1142188-60-0

Basic information

• Product Name: tert-butyl 4-oxo-3,4,5,6-tetrahydropyrido[3,4-d]pyriMidine-7(8H)-carboxylate
• Synonyms: tert-butyl 4-oxo-3,4,5,6-tetrahydropyrido[3,4-d]pyriMidine-7(8H)-carboxylate;TERT-BUTYL 4-HYDROXY-5,6-DIHYDROPYRIDO[3,4-D]PYRIMIDINE-7(8H)-CARBOXYLATE;Seco-Duocarmycin TM
• CAS NO: 1142188-60-0
• Molecular Formula: C₁₂H₁₇N₃O₃
• Molecular Weight: 251.28168
• EINECS: 302-502-1
• Mol File: 1142188-60-0.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-butyl 4-oxo-3,4,5,6-tetrahydropyrido[3,4-d]pyriMidine-7(8H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-oxo-3,4,5,6-tetrahydropyrido[3,4-d]pyriMidine-7(8H)-carboxylate(1142188-60-0)
• EPA Substance Registry System: tert-butyl 4-oxo-3,4,5,6-tetrahydropyrido[3,4-d]pyriMidine-7(8H)-carboxylate(1142188-60-0)

Safety Data

• Hazardous Substances Data: 1142188-60-0(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-oxo-3,4,5,6-tetrahydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate is a chemical compound with a complex structure, containing a pyrido[3,4-d]pyrimidine core. It is a carboxylate ester, which means it has a carboxyl group bound to a tert-butyl group. The compound is a heterocyclic organic molecule that may have potential applications in the fields of pharmaceuticals or organic synthesis. It is likely to be used as a building block in the production of more complex chemical compounds due to its unique structural features. Further research and analysis are required to fully understand its properties and potential uses.

Upstream product

• 3473-63-0 formamidine acetic acid 
• 71233-25-5 ethyl 1-tert-butoxycarbonyl-3-oxopiperidine-4-carboxylate 
• 63876-32-4 4-[benzyl(ethoxycarbonylmethyl)amino]butyric acid ethyl ester 
• 62458-96-2 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 70637-75-1 ethyl 3-oxopiperidine-4-carboxylate 
• 39514-19-7 ethyl 1-benzyl-3-oxo-4-piperidinecarboxylate 
• 6313-33-3 formamidine hydrochloride 

Downstream Products

• 1053656-57-7 4-chloro-5,8-dihydro-6H-pyrido[3,4-d]pyrimidine-7-carboxylic acid tert-butyl ester 
• 1421687-50-4 4-{4-[4-((R)-3-dimethylamino-1-phenylsulfanylmethyl-propylamino)-3-trifluoromethanesulfonyl-benzenesulfonylamino]-8-oxo-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl}-piperidine-1-carboxylic acid tert-butyl ester 
• 1274802-50-4 (R)-N-(7-(1-((4'-chloro-biphenyl-2-yl)methyl)piperidin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide 
• 1274804-71-5 4-((R)-3-dimethylamino-1-phenylsulfanylmethyl-propylamino)-N-(5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl)-3-(trifluoromethanesulfonyl)benzenesulfonamide 
• 1274804-57-7 (R)-tert-butyl 4-(4-(4-(dimethylamino)-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)phenylsulfonamido)-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate 
• 1421687-46-8 tert-butyl 4-methoxy-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate 
• 1196157-06-8 4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine 
• 1274804-70-4 (R)-4-(4-morpholino-1-(phenylthio)butan-2-ylamino)-N-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-(trifluoromethylsulfonyl)-benzenesulfonamide 
• 1274804-52-2 4-{4-[4-((R)-3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-3-trifluoromethanesulfonyl-benzenesulfonylamino]-5,8-dihydro-6H-pyrido[3,4d]pyrimidin-7-yl}-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

DEGRADATION OF ANDROGEN RECEPTOR (AR) BY CONJUGATION OF AR ANTAGONISTS WITH E3 LIGASE LIGAND AND METHODS OF USE

Provided herein are novel bifunctional compounds formed by conjugating AR antagonist moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 Ubiquitin ligase for degradation, and methods of preparation and uses thereof.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

ANTI-ANGIOGENESIS COMPOUND, INTERMEDIATE AND USE THEREOF

Disclosed are an anti-abnormal proliferation of angiogenesis compound represented by formula I, use and intermediate thereof. The compound has good effect against abnormal proliferation of angiogenesis, and the activity of the compound is produced by inhibiting VEGFR2. The compound can be used for treating diseases, such as wet macular degeneration, inflammation, malignant tumor and the like, caused by abnormity of angiogenesis and protein kinases such as VEGFR2, FGFR2 and the like.